The COVID-19 pandemic has given diagnostic technologies unprecedented importance. The rapid diagnosis of individuals suffering from the virus is widely seen as one of humanity’s chief weapons in the battle to bring the present outbreak under control and contain future potential re-emergence.
Against this backdrop, there is a pressing need to both scale up existing diagnostic platforms and to develop new tools for use in the battle against COVID-19. Ambitious government targets for testing of the population require both.
The intellectual property issues involved are significant for several reasons:
- Those looking to bring tests to the market rapidly in response to public health needs must be aware of the risk of infringing third party patents and must take steps to minimize this risk.
- Those developing new diagnostic techniques need to balance the requirements of enabling early access during the crisis while maintaining a viable business model once the immediate urgent need has passed.
- Those involved in research and development of diagnostic assays need to have an awareness of the patent situation in the two territories worst hit by the pandemic, North America and Europe. The possibilities for obtaining patent protection differ greatly between the two jurisdictions.
This webinar will provide perspectives on obtaining and enforcing patents on both sides of the Atlantic, and how to minimize the IP infringement risk when launching a new diagnostic technology in these markets.
Watch recording here: COVID-19 Diagnostics: Intellectual Property Strategies for Rapid Development and Launch on Both Sides of the Atlantic
Agenda: TUESDAY, MAY 19, 2020
12:00 PM MT, 7:00 PM GMT +01:00, 8:00 PM CET
Loren Hulse, Partner, Holland & Hart
Dr. Adrian Bradley, Partner, Cleveland Scott York
Location: Webinar Only